EMPA-REG OUTCOME Trial: A Plain-English Overview of What It Established

By
Published Updated Last reviewed
Clinical medical image for trials empa reg: EMPA-REG OUTCOME Trial: A Plain-English Overview of What It Established

At a glance

| Detail | Value | |---|---| | Trial name | EMPA-REG OUTCOME | | N | 7,020 | | Population | Adults with T2D and established cardiovascular disease | | Intervention | Empagliflozin 10 mg or 25 mg daily | | Comparator | Matching placebo | | Median follow-up | 3.1 years | | Primary endpoint | 3-point MACE (CV death, nonfatal MI, nonfatal stroke) | | Key result | HR 0.86 (95% CI 0.74, 0.99; p = 0.04 for superiority) | | Sponsor | Boehringer Ingelheim / Eli Lilly |

The question the trial asked

Before 2015, no glucose-lowering drug had ever been shown to reduce cardiovascular events in a dedicated outcomes trial. The FDA had mandated cardiovascular outcomes trials (CVOTs) for all new diabetes drugs after the rosiglitazone controversy, but expectations were modest. Most investigators assumed these trials would merely confirm safety, not superiority.

EMPA-REG OUTCOME asked a specific question: in patients who already have type 2 diabetes and established atherosclerotic cardiovascular disease, does adding empagliflozin (an SGLT2 inhibitor sold as Jardiance) to whatever therapies they are already on reduce the rate of major adverse cardiovascular events?

The trial was designed first as a noninferiority study. If empagliflozin cleared that bar, the protocol pre-specified a test for superiority. That two-step gatekeeping matters: many CVOTs stop at noninferiority and declare victory. This one went further.

Who was enrolled (and who was not)

Recruitment took place at 590 sites in 42 countries between 2010 and 2013. To qualify, participants needed:

  • Confirmed type 2 diabetes with an HbA1c between 7% and 10% (later amended to allow up to 9% for drug-naïve patients)
  • Body mass index <45
  • eGFR ≥30 mL/min/1.73 m²
  • Documented cardiovascular disease: prior MI, multivessel coronary artery disease, unstable angina, stroke, or peripheral artery disease

That last criterion is critical. Every participant had established cardiovascular disease at baseline, not just risk factors. About 75% had coronary artery disease, roughly 47% had a prior MI, and approximately 23% had peripheral artery disease. The mean age was 63, about 72% were male, and about 26% were Asian.

Patients on insulin (about 48%), metformin (about 74%), and sulfonylureas (about 43%) could continue those medications. Background cardiovascular therapies were permitted and common: about 77% were on ACE inhibitors or ARBs, 65% on beta-blockers, about 80% on statins, and about 88% on aspirin or other antiplatelet agents.

One important exclusion: patients with eGFR below 30 mL/min were not enrolled. This meant the trial could not speak directly to advanced kidney disease.

What they were given

Participants were randomized 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo, all taken once daily. The trial pooled both empagliflozin arms for the primary analysis (empagliflozin vs. placebo), which is how most of the published results are presented.

Investigators could adjust background glucose-lowering therapy after the first 12 weeks to reach glycemic targets. This is a key design feature. It meant the trial was not comparing tight glucose control to loose glucose control. Both groups could receive intensification. The question was whether empagliflozin added something beyond glucose lowering.

What was measured

The primary endpoint was time to first occurrence of 3-point MACE: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Pre-specified secondary endpoints included the individual MACE components, all-cause mortality, and hospitalization for heart failure.

An independent clinical events committee adjudicated all endpoints while blinded to treatment assignment. The trial required at least 691 confirmed primary events for statistical power.

The results

Primary composite

The primary endpoint occurred in 490 of 4,687 patients on empagliflozin (10.5%) versus 282 of 2,333 on placebo (12.1%). The hazard ratio was 0.86 (95.02% CI, 0.74, 0.99; p = 0.04 for superiority). That 14% relative risk reduction cleared both the noninferiority and superiority thresholds.

Where the benefit came from

The composite result is only the beginning of the story. When the individual MACE components were examined, an unusual pattern emerged:

| Endpoint | Empagliflozin | Placebo | HR (95% CI) | |---|---|---|---| | CV death | 3.7% | 5.9% | 0.62 (0.49, 0.77) | | Nonfatal MI | 4.8% | 5.4% | 0.87 (0.70, 1.09) | | Nonfatal stroke | 3.5% | 3.0% | 1.18 (0.89, 1.56) | | All-cause mortality | 5.7% | 8.3% | 0.68 (0.57, 0.82) | | HF hospitalization | 2.7% | 4.1% | 0.65 (0.50, 0.85) |

The 38% relative reduction in cardiovascular death was enormous and unexpected. All-cause mortality dropped 32%. Hospitalization for heart failure dropped 35%. But nonfatal MI showed only a non-significant trend, and nonfatal stroke went numerically in the wrong direction (also non-significant).

This dissociation puzzled cardiologists. A drug that powerfully reduces CV death but does not clearly reduce heart attacks or strokes does not fit the standard atherosclerosis story. It suggested empagliflozin was working through mechanisms other than plaque stabilization, a point that has generated years of mechanistic research.

Separation of the survival curves

The Kaplan-Meier curves for cardiovascular death began to separate within the first few months and continued to diverge throughout follow-up. This rapid onset argues against a slow atherosclerotic mechanism (plaque regression takes years) and supports hemodynamic and metabolic explanations: reduced preload and afterload from the natriuretic and osmotic diuretic effects of SGLT2 inhibition, improved myocardial energetics, or reduced interstitial fluid congestion.

Kidney outcomes (secondary)

Although not the primary focus of this page, EMPA-REG OUTCOME also showed significant renal benefits. Incident or worsening nephropathy occurred in 12.7% of the empagliflozin group versus 18.8% on placebo (HR 0.61). Doubling of serum creatinine was halved. These findings, published in a companion NEJM paper in 2016, helped launch an entirely separate research program into SGLT2 inhibitors for chronic kidney disease.

HbA1c and metabolic parameters

At 12 weeks, the adjusted mean difference in HbA1c between empagliflozin and placebo was approximately −0.54% for the 10 mg dose and −0.60% for 25 mg. By week 206, the difference narrowed to about −0.24% and −0.36%, respectively, because investigators were allowed to intensify background therapy in the placebo group. Body weight dropped about 2 kg more with empagliflozin. Systolic blood pressure was approximately 4 mmHg lower.

These are modest metabolic improvements. The mortality benefit was far too large and too fast to be explained by a 0.4% HbA1c difference, reinforcing the idea that empagliflozin's cardiovascular effect is not primarily about glucose.

Limitations the authors and the field have acknowledged

Population specificity. Every patient had established CVD. The trial cannot tell you what empagliflozin does for someone with diabetes who only has risk factors. Later trials like DECLARE-TIMI 58 (dapagliflozin) addressed that broader population and found a different benefit pattern, with heart failure hospitalization reduced but no significant effect on MACE.

The stroke signal. The numerically higher stroke rate with empagliflozin (non-significant, HR 1.18) raised concerns. A plausible explanation is that the volume depletion and hemoconcentration caused by SGLT2 inhibition could increase blood viscosity. No subsequent large trial has confirmed a stroke risk, but neither has the concern been entirely dismissed.

Short follow-up. Median follow-up was 3.1 years. Whether the mortality benefit persists, plateaus, or widens over longer periods remains uncertain. No extended follow-up cohort has been published from this trial.

Dose pooling. The 10 mg and 25 mg arms were pooled for the primary analysis. Individual dose analyses showed similar trends, but the trial was not powered to detect differences between doses. The FDA-approved cardiovascular indication is for empagliflozin 10 mg daily.

Industry sponsorship. The trial was funded and operationally managed by Boehringer Ingelheim. The steering committee included both academic and industry investigators. While the independent events committee and the rigorous design provide reassurance, the funder's involvement in data analysis is a standard disclosure.

Generalizability to women and younger patients. About 72% of the cohort was male. The mean age was 63. Results may not apply equally to younger women with T2D and CVD, a group that was simply underrepresented.

What changed after this trial

EMPA-REG OUTCOME published in September 2015 and reshaped type 2 diabetes management almost immediately.

FDA label expansion. In 2016, the FDA added a cardiovascular death reduction indication to the Jardiance prescribing information, making empagliflozin the first diabetes drug to carry such a claim.

Guideline rewrites. The ADA/EASD consensus algorithms were updated to recommend SGLT2 inhibitors as preferred second-line therapy in T2D patients with established CVD or heart failure. The 2019 ESC/EASD guidelines went further, positioning SGLT2 inhibitors as first-line in some CVD patients regardless of HbA1c.

The SGLT2 inhibitor class expansion. EMPA-REG OUTCOME opened the door for DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DAPA-CKD, trials that showed SGLT2 inhibitors benefit patients with heart failure and chronic kidney disease even without diabetes. The drug class moved from "glucose-lowering agent" to "cardiorenal protective agent" in less than a decade.

A shift in how diabetes drugs are evaluated. Before this trial, diabetes outcomes research focused on microvascular complications and HbA1c. EMPA-REG OUTCOME demonstrated that macrovascular outcomes and mortality can and should be primary endpoints. Every major diabetes drug class launched since then has been measured against this standard.

The bottom line for patients and clinicians

For a patient with type 2 diabetes and existing heart disease, the EMPA-REG OUTCOME data make a strong case that empagliflozin reduces the risk of dying from cardiovascular causes. The benefit appeared quickly, was consistent across subgroups, and was accompanied by meaningful reductions in heart failure hospitalization and kidney disease progression.

The drug is not without side effects. Genital mycotic infections were more common (about 6.4% vs. 1.8%). Urinary tract infections occurred at similar rates. Diabetic ketoacidosis, while rare, is a recognized class risk.

For the right patient, the risk-benefit ratio is favorable. The question clinicians now face is not whether to use SGLT2 inhibitors in this population, but how early and in what combination.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. PubMed
  2. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334. PubMed
  3. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. PubMed
  4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357. PubMed
  5. Jardiance (empagliflozin) prescribing information. U.S. Food and Drug Administration. FDA Label